Clinical trials: Myocardial Infarction, pill or tablet or capsule or oral, open to volunteers
- Condition Myocardial Infarction
- Drug or intervention pill OR tablet OR capsule OR oral
- Status Open to volunteers
Myocardial Infarction, Coronary Stenosis
Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI
Study rationale: to evaluate clinical and prognostic relevance of microvascular dysfunction, coronary flow reserve and cardioprotective effects of iv administration of esmolol in patients with myocardial infarction.
- Conditions
- Myocardial Infarction, Coronary Stenosis, Coronary Microvascular Dysfunction
- Trial name
- ESMO-VASCMI (NCT06376630)
- Testing
- Esmolol Hcl 10Mg/Ml Inj
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Study Background \& Purpose: The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI).
- Conditions
- No Reflow Phenomenon, Reperfusion Injuries, Myocardial, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT07898709
- Testing
- Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment
- Where
- 4 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Acute Coronary Syndromes (ACS), Iron Deficiencies
Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
The goal of this phase IV, open-label, randomized clinical trial is to evaluate whether intravenous iron improves quality of life in adults aged 65 years and older with iron deficiency after an acute coronary syndrome (ACS).
- Conditions
- Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)
- Trial name
- HI-COR-65 (NCT07476859)
- Testing
- Ferric Carboxymaltose Injection [Ferinject]
- Where
- 9 sites in Spain
- Volunteers
- 538 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Acute Myocardial Infarction (AMI), Gastrointestinal Bleeding
Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction
This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction…
- Trial name
- PCAB-AMI (NCT07467213)
- Testing
- Zastaprazan, Proton Pump Inhibitors (PPI)
- Where
- South Korea
- Volunteers
- 5,000 people
- Sponsor
- Samsung Medical Center
Left Ventricular Thrombus, Acute Myocardial Infarction
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear.
- Trial name
- RESOLVE-AMI (NCT06515730)
- Testing
- Apixaban, Warfarin
- Where
- 16 sites in Sweden
- Volunteers
- 212 people
- Sponsor
- Karolinska Institutet
Cardiogenic Shock, Acute Myocardial Infarction
Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
This is a prospective, single-center, observational pilot study of the investigational NIRSense Tissue Oximetry Sensor System (Envello Core), a noninvasive wearable sensor patch that uses near-infrared spectroscopy (NIRS) and…
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, Acute Decompensated Heart Failure
- Trial name
- NCT07825363
- Testing
- NIRSense Tissue Oximetry Sensor System
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NIRSense Inc.
Acute Myocardial Infarction
Intervention of Suxiao Jiuxin Pill on Instability of Vulnerable Plaque in Acute Myocardial Infarction
The incidence of cardiovascular disease is still high in China under the condition of non-standard treatment of Western medicine.
- Trial name
- NCT05466968
- Testing
- Suxiao Jiuxin Pills
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Xiaolu Li
ST-segment Elevation Myocardial Infarction (STEMI)
A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI
This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether "butylphthalide +PCI" combined treatment mode on the basis of traditional drug therapy…
- Trial name
- RISE (NCT06704685)
- Testing
- Butylphthalide
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall, Cardiovascular Diseases
Impact, Cost, and Sustainability of a Customized, Low-Cost Intervention to Reduce Cardiovascular Disease Burden in India: A Cluster Randomized Trial
The ICRAG-2 project aims to assess the impact, cost-effectiveness, and sustainability of a low-cost, multipronged intervention package to reduce cardiovascular disease (CVD) burden in India.
- Trial name
- ENABLE (NCT06836661)
- Testing
- FDC and TLC and medication adherance, Patients will Enhanced Usual Care (EUC)
- Where
- India
- Volunteers
- 1,560 people
- Sponsor
- St. John's Research Institute
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Acute Myocardial Infarction, Severe Periodontitis
Impact of Treating Severe Periodontitis on Inflammatory Activity of Atheromatous Plaques in Patients With Acute Myocardial Infarction (AMI)
Multicenter randomized clinical trial with two arms in patients hospitalized for an AMI nested in the Frenchie registry. Periodontal therapy is performed by periodontists in the intervention group versus treatment by dental…
- Conditions
- Acute Myocardial Infarction, Severe Periodontitis, Carotid Atherosclerosis
- Trial name
- PAROCARD (NCT04046237)
- Testing
- Periodontal treatment
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myocardial Infarction (MI), Cardiovascular Events
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy
One in 4 adults between 50 and 80 reports taking regular aspirin. The prevalence of aspirin uses increases with age as well as co-morbid vascular diseases.
- Conditions
- Myocardial Infarction (MI), Cardiovascular Events, Post Polypectomy Bleeding in Antiplatelet Patients
- Trial name
- NCT07052799
- Testing
- Aspirin 80mg
- Where
- Hong Kong
- Volunteers
- 2,514 people
- Sponsor
- Chinese University of Hong Kong
ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI)
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
The goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart…
- Conditions
- ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
- Trial name
- TEMPO-STEMI (NCT07749014)
- Testing
- empagliflozin
- Where
- Pakistan
- Volunteers
- 480 people
- Sponsor
- Rehman Medical Institute - RMI
Myocardial Infarction (MI)
Optimize Risk Prediction After Myocardial Infarction: The ORACLE Study
Background. Myocardial infarction (MI) is a leading cause of death worldwide. After MI, longterm antithrombotic therapy is crucial to prevent recurrent events, but increases bleeding, that also impacts morbidity and mortality.
- Trial name
- ORACLE (NCT06993415)
- Testing
- data collection
- Where
- Spain
- Volunteers
- 750 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Cardiogenic Shock Post Myocardial Infarction
Ivabradine in the Acute Management of Cardiogenic Shock
Brief Summary: The IVASHOCK trial investigates whether ivabradine can achieve at least one-class improvement in SCAI cardiogenic shock classification compared to placebo, and evaluates its safety profile in patients with…
- Trial name
- IVASHOCK (NCT07714746)
- Testing
- Ivabradine 5mg Tab
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Chronic Stable Heart Failure
Qishenyiqi for Ventricular Remodeling After Myocardial Infarction
The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported.
- Trial name
- NCT06699407
- Testing
- Qishenyiqi dripping pills
- Where
- 3 sites in China
- Volunteers
- 210 people
- Sponsor
- Qilu Hospital of Shandong University
Myocardial Infarction
Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI
Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile.
- Trial name
- NCT05880355
- Testing
- Dapansutrile
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Myocardial Infarction, Acute, Periodontitis
PERIODONTAL HEALTH IN PATIENTS ACUTELY ADMITTED FOR MYOCARDIAL INFARCTION: A CASE CONTROL STUDY
Heart attack remains a major cause of death in adult population worldwide and especially within Scotland. A large portion of the general population has an increased risk of suffering from a heart attack because of their genetic…
- Trial name
- PEDICAD (NCT04719026)
- Testing
- Full-mouth periodontal examination using computerised Florida probe
- Where
- United Kingdom
- Volunteers
- 320 people
- Sponsor
- University of Aberdeen
Stroke, Coronary Arterial Disease (CAD)
Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome
The Western diet, rich in fat and sugar, contributes to cardiovascular risk and alters the body metabolism, specifically through the modulation of the microbiome.
- Conditions
- Stroke, Coronary Arterial Disease (CAD), Myocardial Infarction (MI), Diabetes Mellitus
- Trial name
- CALGUT (NCT07173062)
- Testing
- Spirulina Arthrospira platensis (microalgae), Gelidium corneum
- Where
- Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade do Porto